Concepedia

Author

Emma Dean

AstraZeneca (United Kingdom)ORCID

Also Known As

Dean, E., Dean, Emma, E Dean, E J Dean, E. Dean, E. Déan, E.J. Dean, Emma Dean, Emma J Dean, Emma J. Dean

284

Publications

5.4K

Citations

37

H-Index

65

Concepts

All Affiliations

AstraZeneca (United Kingdom)The Christie NHS Foundation TrustUniversity of ManchesterInstitute of Cancer ResearchAstraZeneca (United States)
ED

About

Emma Dean is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

36

1.7K

2

Health Sciences

5

5

293

3

Biochemistry

2

2

99

4

Natural Sciences

1

1

77

5

Public Health

1

1

302

Emma Dean

×

75

Publications

4.7K

Citations

35

H-Index

YearCitations

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada,

Nature Communications

2019

327

AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue,

Journal of Clinical Oncology

2017

315

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Dominic G. Rothwell, Mahmood Ayub, Natalie Cook,

Nature Medicine

2019

302

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau,

EClinicalMedicine

2021

250

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong,

The Lancet Oncology

2019

217

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya,

Oncogene

2020

179

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Jean‐Charles Soria, Hui Gan, Sarah P. Blagden,

Annals of Oncology

2016

140

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo,

Clinical Cancer Research

2017

139

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Bristi Basu, Emma Dean, M. Puglisi,

Clinical Cancer Research

2015

126

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

Joaquı́n Mateo, Víctor Moreno, Avinash Gupta,

Targeted Oncology

2016

126

Page 1